SynthesisFrontiers in immunology2026
Gout, hyperuricemia, and male reproductive health: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gout is an inflammatory arthritis characterized by hyperuricemia in humans. Male patients with gout or hyperuricemia have a wide range of reproductive health challenges. However, research on the sexual and reproductive health of male patients with gout or hyperuricemia remains limited. Objective: This systematic review and meta-analysis investigated the impact of gout and/or hyperuricemia and its associated factors on male sexual and reproductive health. Methods: The PubMed, Cochrane, Embase, Web of Science, Wanfang Data, and China National Knowledge Infrastructure (CNKI) databases were searched for relevant articles from January 2000 to October 2025. Two reviewers extracted the data and completed quality assessment using the Newcastle-Ottawa Scale and the Agency for Healthcare Research and Quality checklist. Meta-analysis was conducted using Review Manager 5.4 and Stata 18.0. The protocol was registered on PROSPERO (CRD 420261302205). The outcomes such as sexual function, reproductive hormones, and fertility were evaluated. Results: In the literature search, 1,527 articles were retrieved. Among these, 11 studies met the inclusion criteria. This meta-analysis included 104,277 patients with gout or hyperuricemia and 342,621 control subjects. The meta-analysis results showed that the risk of erectile dysfunction was higher in patients with gout (RR = 1.37; 95% CI = 1.14 to 1.65, Conclusion: Male patients with gout or hyperuricemia are more prone to erectile dysfunction and lower levels of reproductive hormones. Patients with gout showed significantly lower testosterone levels in the subgroup analyses. These findings emphasize the clinical need for increased awareness of male reproductive health problems in men with gout and implementation of effective intervention measures. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261302205.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.